瑞他鲁肽 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-24 and is reviewed periodically as new material appears.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Delta hexatoxin Hv1 (δ-HXTX-Hv1a, Versutoxin, or Versutotoxin, formerly known as Delta atracotoxin Hv1 and δ-ACTX-Hv1a) is a neurotoxic component found in the venom of the Australian funnel web spider (Atrax robustus). Delta hexatoxin Hv1 can result in fatality for primates, by downregulating the inactivation of voltage gated sodium ion channels (VGSCs) found in motor neurons. The structure of versutoxin contains a central beta region with a cystine knot motif, commonly found in other neurotoxic polypeptides, but not found in sea anemone or alpha-scorpion toxins despite their similar effects in terms of sodium channel modulation.
== External links == Deltamethrin Technical Fact Sheet - National Pesticide Information Center Deltamethrin General Fact sheet - National Pesticide Information Center Pyrethrins and Pyrethroids Fact Sheet - National Pesticide Information Center Deltamethrin Pesticide Information Profile - Extension Toxicology Network Deltamethrin Development Exposure - FASEB Journal
Some sources say that the El Niños of 2006-07 and 2014-16 were also Central Pacific El Niños. Recent years when La Niña Modoki events occurred include 1973–1974, 1975–1976, 1983–1984, 1988–1989, 1998–1999, 2000–2001, 2008–2009, 2010–2011, and 2016–2017. The recent discovery of ENSO Modoki has some scientists believing it to be linked to global warming. However, comprehensive satellite data go back only to 1979. More research must be done to find the correlation and study past El Niño episodes. More generally, there is no scientific consensus on how/if climate change might affect ENSO. There is also a scientific debate on the very existence of this "new" ENSO. A number of studies dispute the reality of this statistical distinction or its increasing occurrence, or both, either arguing the reliable record is too short to detect such a distinction, finding no distinction or trend using other statistical approaches, or that other types should be distinguished, such as standard and extreme ENSO. Likewise, following the asymmetric nature of the warm and cold phases of ENSO, some studies could not identify similar variations for La Niña, both in observations and in the climate models, but some sources could identify variations on La Niña with cooler waters on central Pacific and average or warmer water temperatures on both eastern and western Pacific, also showing eastern Pacific Ocean currents going to the opposite direction compared to the currents in traditional La Niñas.
Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. The US Food and Drug Administration considers it to be a first-in-class medication.
Uranium-235 (235U or U-235) is an isotope of uranium making up about 0.72% of natural uranium. Unlike the predominant isotope uranium-238, it is fissile, i.e., it can sustain a nuclear chain reaction. It is the only fissile isotope that exists in nature as a primordial nuclide and was discovered in 1935 by Arthur Jeffrey Dempster. The release of energy from the fission of Uranium-235 powers most nuclear reactors and nuclear weapons. Uranium enrichment is the process of taking natural uranium and increasing the proportion of uranium-235. Some reactor types can use natural uranium directly, while nuclear weapons and some others reactor types require uranium enriched in U-235. Uranium-235 has a half-life of 704 million years. Its fission cross section for slow thermal neutrons is about 584.3±1 barns. For fast neutrons it is on the order of 1 barn. Most neutron absorptions induce fission, though a minority (about 15%) result in the formation of uranium-236.
Sources: en.wikipedia.org
Binding of PPARγ to coactivators appears to reduce the levels of coactivators available for binding to pro-inflammatory transcription factors such as NF-κB; this causes a decrease in transcription of a number of pro inflammatory genes, including various interleukins and tumour necrosis factors.
==== RNA is multifunctional ==== RNA is multifunctional, its primary function is to encode proteins, according to the instructions within a cell's DNA. They control and regulate many aspects of protein synthesis in eukaryotes. RNA encodes genetic information that can be translated into the amino acid sequence of proteins, as evidenced by the messenger RNA molecules present within every cell, and the RNA genomes of a large number of viruses. The single-stranded nature of RNA, together with tendency for rapid breakdown and a lack of repair systems means that RNA is not so well suited for the long-term storage of genetic information as is DNA. In addition, RNA is a single-stranded polymer that can, like proteins, fold into a very large number of three-dimensional structures. Some of these structures provide binding sites for other molecules and chemically active centers that can catalyze specific chemical reactions on those bound molecules. The limited number of different building blocks of RNA (4 nucleotides vs >20 amino acids in proteins), together with their lack of chemical diversity, results in catalytic RNA (ribozymes) being generally less-effective catalysts than proteins for most biological reactions.
doi:10.1021/acs.jproteome.5b00827. ISSN 1535-3893. PMC 5706558. PMID 26435392. Omenn, Gilbert S.; Lane, Lydie; Lundberg, Emma K.; Beavis, Ronald C.; Nesvizhskii, Alexey I.; Deutsch, Eric W. (2015). "Metrics for the Human Proteome Project 2015: Progress on the Human Proteome and Guidelines for High-Confidence Protein Identification". Journal of Proteome Research. 14 (9): 3452–3460. doi:10.1021/acs.jproteome.5b00499. ISSN 1535-3893. PMC 4755311. PMID 26155816. Fenyö, David; Beavis, Ronald C. (2015). "The GPMDB REST interface". Bioinformatics. 31 (12): 2056–2058. doi:10.1093/bioinformatics/btv107. ISSN 1367-4803. PMID 25697819.
In addition to the primary methods above, another method exists to measure the moisture content of wood: an electronic moisture meter. Pin and pinless meters are the two main types of moisture meters. Pin meters require driving two pins into the surface of the wood while making sure that the pins are aligned with the grain and not perpendicular to it. Pin meters provide moisture content readings by measuring the resistance in the electrical current between the two pins. The drier the wood, the more resistance to the electrical current, when measuring below the fiber saturation point of wood. Pin meters are generally preferred when there is no flat surface of the wood available to measure Pinless meters emit an electromagnetic signal into the wood to provide readings of the wood's moisture content and are generally preferred when damage to the wood's surface is unacceptable or when a high volume of readings or greater ease of use is required.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。